Home

 

 

Latest Discussions

Member Spotlight

Latest Specialty News

  • A clinical trial is underway within the Children’s Oncology Group to assess the efficacy of CPX-351 in children and adolescents with relapsed acute myeloid leukemia. Previous research demonstrated the safety and efficacy of CPX-351 (Vyxeos, Celator) — a nanoscale co-formulation of cytarabine and daunorubicin — in adults with AML. Researchers now hope to achieve the same results in the pediatric population.
  • Awards and Recognition

    APHON members are eligible to nominate and/or receive awards. The awards are presented to pediatric hematology/oncology nurses who have been recognized as going above and beyond in their profession or in their participation in APHON. Visit the APHON website for more details about each award. Nominations must be received by May 31, 2017.
  • Photo Contest

    Members are encouraged to submit photos from their day to day lives into the annual photo contest. All submissions must be received by APHON Headquarters no later than June 30 to be eligible! Click here to learn more.

How to Login

How to Add a Personal Contact

How To Update Your Profile

How to Post & Reply to a Discussion

How to Post to the Library